Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 58 от 240

Набира участници Фаза 1

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Non-muscle Invasive Bladder Cancer

The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow. It includes people whose cancer has come back or hasn't gone away after receiving standard treatments like BCG. It may also include people who, based on their doctor's opinion, cannot receive standard treatments or those treatments are not available to them. The study has three parts: * Part 1 (monotherapy dose escalation) will test PF-08052667 as a single-agent at increasing dose levels in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 2 (combination dose escalation) will test PF-08052667 in combination with BCG and/or sasanlimab (fixed dose) in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 3 (dose optimization and expansion) will further test PF-08052667 as a single agent or in combination with BCG and/or sasanlimab, at the dose(s) based on findings from Part 1 and Part 2 in participants with certain bladder cancer including those who has never received standard treatments. All participants will receive the study drug PF-08052667. Only participants in Part 2 and Part 3 of the study will also receive BCG and/or sasanlimab. PF-08052667 will be given as an intravesical infusion, which means it will be injected directly into the bladder. Sasanlimab will be given as a subcutaneous injection, which means it will be injected under the skin. For all parts, treatment with study medicines will continue until either a participant has decided to stop taking part in the study or is asked to leave the study for various reasons or up to about 2 years, whichever occurs first. Duration of trial participation for each participant will vary as long-term follow-up will continue after treatment discontinuation until loss to-follow-up or death, or until the study is stopped by the sponsor.

Начало: 06.11.2025 Край: 28.01.2033 Възраст: от 18 г.

France, Israel, South Korea +2 Pfizer NCT07206225

Набира участници Фаза 2

Improving Vaccine Protection for Older Adults

Immune System Responses and Trained Immunity After AS01 Administration Healthy Adult

As people grow older, their immune system - the body's natural defence against diseases - becomes weaker, making them more vulnerable to infections and less responsive to vaccines. This was clearly seen during the COVID-19 pandemic, where older adults were more likely to develop severe illness. Researchers have made an interesting discovery about AS01, an ingredient already used in successful vaccines like the shingles vaccine. They found clues that AS01 might work like a general fitness trainer for the immune system, potentially making it stronger and better at fighting off various types of infections, not just specific ones. To confirm this possibility, we are conducting this research study with adults aged 21-59 to test whether AS01 by itself can boost and train the immune system, how long this boost lasts, and if it actually helps you fight off other infections more effectively.

Начало: 06.11.2025 Край: 28.02.2029 Възраст: 21–59 г.

Singapore Singapore General Hospital NCT07527247

Набира участници

Influence of Dressings on Skin pH Alterations in Simulated Skin Folds in Healthy Subjects

Skin Folds

This study investigates the effect of different dressings on skin pH when applied to a simulated skin fold environment.

Начало: 05.11.2025 Край: 30.04.2026 Възраст: 18–80 г.

Sweden Essity Hygiene and Health AB NCT07547488

Набира участници

A Study to Evaluate the Performance of a Wireless Optical Sensor Capsule in Detection of UGIB

Melena Gastrointestinal Bleeding Hematemesis

Upper gastrointestinal bleeding (UGIB) is a common and potentially lethal medical emergency, which requires hospitalization and healthcare resources. Despite the changing epidemiology and advancement of endoscopic therapy in the recent decade, the all-cause mortality of UGIB remains high (\>2%). An accurate risk stratification is necessary to triage patients into low- or high-risk groups, in order to inform clinicians for the necessity and timing of urgent endoscopy. However, existing pre-endoscopy risk scores, such as the Glasgow-Blatchford score (GBS), Rockall score and AIMS65 score, are suboptimal in predicting relevant clinical outcomes. An alternative strategy for risk stratification is urgently warranted in patients with UGIB to guide the next step of management. In a pre-clinical study, the sensitivity and specificity of HemoPill® prototype were 95% and 87.5% respectively, when the sensors were positioned close to the bleeding point. Furthermore, several human clinical studies have proven the feasibility and accuracy of HemoPill® in healthy volunteers and patients with suspected UGIB. Capsule ingestion was well tolerated with no device-related adverse event or capsule retention. All patients with negative HI were found to have no active endoscopic bleeding (true negative, 100%, 17/17). In patients with bleeding \>20ml, true positive HI signals were detected (100%, 2/2) In a retrospective multi-center study, 61 patients with suspected UGIB were recruited to use HemoPill®. Among the capsule-positive cases, subsequent endoscopy confirmed active bleeding in 57% (20/35) of them. None of the capsule-negative patients rebled (0%, 0/25), which prevented unnecessary emergent endoscopy in 72% of them (18/25).

Начало: 05.11.2025 Край: 30.04.2028 Възраст: от 18 г.

Hong Kong Chinese University of Hong Kong NCT06715293

Набира участници Фаза 3

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

Locally Advanced Cervical Adenocarcinoma Locally Advanced Cervical Adenosquamous Carcinoma Locally Advanced Cervical Squamous Cell Carcinoma Stage IIIA Cervical Cancer FIGO 2018 +4

This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding induction chemotherapy to the usual treatment of chemotherapy and radiation followed by maintenance may be more effective in treating patients with high risk, locally advanced cervical cancer.

Начало: 05.11.2025 Край: 31.12.2030 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT07061977

Набира участници Фаза 2

AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)

Colorectal Cancer Liver Metastases (CRLM)

This is a prospective, randomized controlled, single-center phase II clinical study. It aims to compare the efficacy of AK104 plus radiotherapy combined with standard therapy versus standard therapy as first-line treatment for liver metastases from metastatic colorectal cancer.

Начало: 04.11.2025 Край: 01.11.2028 Възраст: от 18 г.

China Fudan University NCT07544784

Набира участници

Clinical Study to Evaluate the Safety and Effectiveness of Arcevo LSA

Aortic Arch Aneurysm Aortic Arch Dissection Chronic Aortic Dissection Acute Aortic Dissection

The goal of this clinical trial is to learn if the Arcevo LSA stent graft can safely and effectively treat patients that have an acute or chronic aortic dissection and/or aneurysm that involves the aortic arch and the descending thoracic aorta, with or without the involvement of the ascending aorta.

Начало: 04.11.2025 Край: 01.07.2032 Възраст: 18–80 г.

United States Artivion Inc. NCT07089576

Набира участници

Pilot Randomized Study for Treatment Volume De-Escalation for Spinal Metastases With Stereotactic Body Radiation Therapy

Metastases to Bone

A single centre, non-profit, randomised, unblinded pilot study on volume definition for spinal stereotactic body radiation therapy treatment. Randomization will be 1:1 between two types of SBRT treatment for spinal metastases. The statistical unit will be the individual vertebral metastasis. Multiple metastases will be randomized and evaluated independently.

Начало: 04.11.2025 Край: 04.05.2029 Възраст: от 18 г.

Italy IRCCS Sacro Cuore Don Calabria di Negrar NCT07538024

Набира участници Фаза 1/2

Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors

Glioma CNS Tumor, Adult CNS Tumor, Childhood

This clinical trial is a 2-phase trial designed to evaluate the safety of tarlatamab in combination with a fixed dose of metronomic temozolomide in adolescents and adults with CNS tumors (stratified into two age-based cohorts), and to assess the clinical activity of this therapeutic strategy in three parallel, histology-defined cohorts (IDH-mutant glioma, other gliomas, and other CNS tumors). A pre-screening to detect DLL3 expression by IHC on archival tumor sample must be performed before the therapeutic part. Only patients with DLL3 positive tumor on IHC can be enrolled in the therapeutic part. This pre-screening must be optimally performed during the ongoing treatment line i.e. before documented progression to not delay treatment starts at time of progression. Tumor samples (surgery or biopsy specimen) will be sent to a central lab for IHC testing.

Начало: 04.11.2025 Край: 01.10.2030 Възраст: от 12 г.

France Centre Leon Berard NCT07243470

Набира участници Фаза 1

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Locally Advanced Alveolar Soft Part Sarcoma Metastatic Alveolar Soft Part Sarcoma Locally Advanced Non Small Cell Lung Cancer Metastatic Non Small Cell Lung Cancer +6

Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow. One of these drugs (atezolizumab) is approved to treat certain cancers. Researchers want to find out if lower doses of this drug might provide the same benefit with fewer adverse effects. Objective: To test different doses and timing of atezolizumab for people with cancer. Eligibility: People aged 18 years and older with cancer that has spread locally or to other organs. They must be eligible for treatment with the study drug. Design: Participants will be screened. They will have blood tests and imaging scans. They will provide a sample of tissue from their tumor. Atezolizumab is administered through a tube attached to a needle inserted into a vein in the arm. Participants will take this drug alone or combined with other drugs prescribed for their care. The first 2 treatments will be done per the FDA recommended dose and schedule. Before administering the second dose of the study drug, researchers will check the level of the drug in the participant s blood. Depending on those results, their 3rd dose will be scheduled 2 to 6 weeks later. For the 3rd dose of the study drug, participants will switch to the FDA minimum dosage. Dosages of any other drugs will not change. Researchers will continue to test the levels of the drug in participants blood before each treatment for 16 weeks. After that, these levels will be tested every 3 months. Study treatment may last up to 2 years.

Начало: 04.11.2025 Край: 31.01.2028 Възраст: 18–120 г.

United States National Cancer Institute (NCI) NCT06066138

Набира участници

Study of the Effects of Time-Restricted Feeding on the Immune Function of Individuals With Obesity

Obesity and Obesity-related Medical Conditions

The goal of this randomized trial is to: 1) investigate the immunological landscape of patients with obesity and conduct an in-depth functional characterization of their immune system; and 2) precisely define the effects of time-restricted feeding (TRF) on immune function in patients with obesity; 3) uncover the underlying mechanisms by which TRF modulates the immune system patients with obesity through a multi-omics approach. The main questions it aims to answer are: i) what is the underlying cause of impaired immunocompetence in patients with obesity? ii) how nutritional interventions improve the immune function of patients with obesity? Patients with obesity following TRF (8 h eating window ranging from 6-8 am to 14-16 pm) will be compared to patients with obesity without TRF control schedule (14h eating window ranging from 6-8 am to 8-10 pm). In addition to patients with obesity, the present study aims to recruit a group of a reference healthy group (BMI between 18.5-24.9 kg/m²) that will not receive any nutritional intervention. The following endpoints will be collected: Body weight and composition using Bioelectrical Impedance Analysis, resting energy expenditure (REE) using indirect calorimetry, blood glucose levels using a continuous glucose monitoring (CGM) device, metabolic parameters (fasting blood glucose levels, C-peptide, HbA1c, insulin, HOMA-IR, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, hepatic enzymes), and cytokine profile. Blood and stool, samples will be collected to establish metagenomic, transcriptomic, cytomic and metabolomic analyses.

Начало: 03.11.2025 Край: 15.09.2027 Възраст: 18–64 г.

France Assistance Publique - Hôpitaux de Paris NCT06899997

Набира участници Фаза 2

A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease

Still´s Disease

The study is a phase II trial designed to evaluate the clinical efficacy, safety, and tolerability of MAS825 in pediatric and adult participants with Still's disease

Начало: 03.11.2025 Край: 24.05.2029 Възраст: 1–100 г.

Canada, France, Germany +5 Novartis Pharmaceuticals NCT07203001

Набира участници

Health Web Te@m (1.0) an Interprofessional Web-based Group Intervention Supporting Healthy Ageing

Healthy Older Adults

The goal of this study is to evaluate the feasibility of Health Web - Te@m 1.0 for older adults in selected primary healthcare settings in northern Sweden. More specifically, the feasibility will be assessed through the following objectives: * Explore older adults' experiences of the intervention process, acceptability, and perceptions of the value of participating in Health Web - Te@m. * Explore professionals' experiences of acceptability, value, and implementation potential of delivering Health Web - Te@m in primary healthcare settings. * Evaluate adherence to Health Web - Te@m among older adults and professionals. * Evaluate the assessments' ability to detect potential outcomes of Health Web - Te@m.

Начало: 03.11.2025 Край: 01.12.2026 Възраст: от 65 г.

Sweden Luleå Tekniska Universitet NCT07545915

Набира участници

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

Bladder Cancer Recurrent Bladder Cancer Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder cancer is the most common urinary tract cancer and the 6th most common cancer in the US. Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians. The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer Study 2 (CISTO2) has the potential to fill these critical evidence gaps, change care pathways for the management of NMIBC (non-muscle-invasive bladder cancer), and provide for personalized, patient-centered care. The purpose of CISTO2 is to conduct a large prospective study that directly compares the impact of bladder sparing therapies versus bladder removal in recurrent high-grade NMIBC patients on financial toxicity, clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs).

Начало: 03.11.2025 Край: 01.12.2028 Възраст: от 18 г.

United States University of Washington NCT07225127

Набира участници Фаза 2

A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse

Smoking

This study evaluates the efficacy and safety of brenipatide when compared to placebo for reducing the risk of relapse to cigarette smoking in adults who have recently quit. Study participation will last approximately 34 weeks with up to 17 study visits, which includes a 2-week screening period, 24-week treatment period, 8-week safety follow-up period. .

Начало: 03.11.2025 Край: 01.02.2027 Възраст: 18–75 г.

China, Japan, United States Eli Lilly and Company NCT07223840

Набира участници Фаза 2

Fentanyl Versus Hydromorphone in Patients on Mechanical Ventilation

Mechanical Ventilation Sedation and Analgesia Critical Care, Intensive Care

Patients with respiratory failure who require mechanical ventilation are not only at risk of death, but also of complications of prolonged ICU stay. Patients may have significant functional decline, impact in quality of life, develop psychiatric disorders and at long-term can lead to significant cost to society. Although sedation and analgesia are considered only supportive therapy, several studies have shown that in patients on mechanical ventilation, different approaches can have significant impact on patient centered outcomes. However, to date, randomized clinical trials on critically ill patients have mostly evaluated the sedative agent but not the analgesic agent. Although morphine and its derivates are the most common used opioid analgesic agents in the critical care setting, only some retrospective studies and some prospective studies compared them head-to-head (ramifentanyl versus morphine and fentanyl versus morphine). Current guidelines recommend choosing the analgesic agent based on pharmacokinectics, physician experience and side-effects profile. To evaluate the differences of two standard-of-care analgosedation agents, the FenHydro trial will be a cluster randomized, pragmatic, pilot and feasibility superiority clinical trial in mechanically ventilated patients in the ICU. The main question the study hopes to answer is whether there is any difference in morphine milligram equivalents administered during mechanical ventilation.

Начало: 03.11.2025 Край: 01.06.2026 Възраст: от 18 г.

United States Beth Israel Deaconess Medical Center NCT07224620

Набира участници

Evaluation of Zygomatic Implant Placement Accuracy Using Fully Metallic vs Resin-based Static Surgical Guides in Severely Atrophic Maxilla

Atrophic Edentulous Maxilla Zygomatic Implants Guided Surgery Dental Implant +1

Some patients lose a large amount of bone in the upper jaw. When this happens, it can be difficult to place regular dental implants. In these cases, special implants called zygomatic implants can be used. These implants are longer than normal implants and are fixed in the cheekbone, which usually has enough bone to support them. They can help support fixed teeth for patients with severe bone loss in the upper jaw. Placing zygomatic implants requires careful planning and high accuracy. To help guide the surgeon during the operation, a surgical guide can be used. A surgical guide is a custom-made device that helps the surgeon place the implant in the planned position. Surgical guides can be made from different materials. The most common type is made from resin (a strong plastic material) using 3D printing. Recently, fully metallic surgical guides have been developed. These metal guides may be stronger and more stable during surgery, but it is not yet clear if they improve the accuracy of implant placement. The purpose of this study is to compare the accuracy of metal surgical guides and resin surgical guides when placing zygomatic implants in patients with severe bone loss in the upper jaw. Patients included in the study will undergo a clinical examination and a CT scan before surgery to plan the implant positions. During the surgery, each patient will receive zygomatic implants on both sides of the upper jaw. On one side, the implants will be placed using a metal surgical guide, and on the other side, they will be placed using a resin surgical guide. This allows the two types of guides to be compared in the same patient. After the surgery, another CT scan will be taken to check the final position of the implants. The planned implant position will be compared with the actual position after surgery to measure the accuracy of placement. The results of this study will help determine whether metallic surgical guides or resin surgical guides provide better accuracy when placing zygomatic implants. Participation in this study is voluntary. All patients will receive full information about the study and will sign a consent form before participating.

Начало: 03.11.2025 Край: 01.05.2026 Възраст: от 18 г.

Egypt Future University in Egypt NCT07551024

Набира участници

Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab

Diabete Mellitus Retina Vein Occlusion Age Macular Degeneration

Bevacizumab, an anti-VEGF (vascular endothelial growth factor) agent used in the treatment of diabetic retinopathy and macular edema associated with retinal vein occlusion, is commonly administered in ophthalmology clinics through intravitreal injection. The systemic use of bevacizumab has been associated with serious conditions such as thromboembolism and bleeding. Although intravitreal bevacizumab is administered in smaller amounts and has limited systemic circulation, it requires repeated injections over a long period. These long-term intravitreal anti-VEGF therapies may lead to adverse outcomes, particularly thromboembolism, due to systemic inhibition of VEGF. However, limited information is available regarding the potential effects of this treatment on the systemic and cardiovascular systems. To evaluate this risk, the study aims to assess changes in the activities of paraoxonase 1 (PON1), acetylcholinesterase (AChE), and butyrylcholinesterase (BChE), which are closely associated with lipid metabolism, coronary artery disease, and atherosclerosis. These enzymes are known biomarkers of cardiovascular health and play significant roles in protection against oxidative stress and inflammation. For this purpose, a case-control study is planned. Serum BChE and PON1 activities, as well as triglyceride (TG)/high-density lipoprotein (HDL) and TG/glucose ratios, will be determined in patients receiving repeated intravitreal bevacizumab injections and in control groups, and cardiovascular disease risk will be assessed. This study may help us better understand the safety profile of this treatment by revealing the effects of bevacizumab on serum enzyme activities and cardiovascular risk factors. These findings could contribute to optimizing treatment strategies in clinical practice.

Начало: 03.11.2025 Край: 10.07.2026 Възраст: 50–80 г.

Turkey (Türkiye) Ataturk University NCT07550777

Набира участници

Amino Acid Oxidation of Whole-Food Protein: a Dose-Response Crossover Trial in Young Adults

Protein Metabolism

The purpose of this study is to assess the amino acid oxidation dose-response relationship of ingested whole-food protein in healthy adults. In a randomized, crossover design, 20 young, healthy adult males and females aged 18-35 years, will consume a dinner consisting of 0.32, 0.74, and 1.32 g protein･kg BM-1 (corresponding to 1, 2, and 4 minced beef patties, respectively) during 3 separate experimental trials.The main study endpoint is the amino acid oxidation of ingested protein over a 24-h period.

Начало: 01.11.2025 Край: 01.03.2027 Възраст: 18–35 г.

Netherlands Maastricht University Medical Center NCT07547176

Набира участници

CAIX PET/ CT Guided Radiation Therapy in CcRCC.

Radiation Therapy Metastatic Renal Cancer Recurrent Renal Cell Cancer

This is a prospective, single-arm study in adults with recurrent or metastatic clear cell renal cell carcinoma (ccRCC). Participants will receive standard systemic therapy (targeted therapy plus anti-PD-1 immunotherapy) and undergo dual PET/CT imaging (FDG PET/CT and a CAIX-targeted PET/CT) to map disease sites. When feasible, PET/CT-visible lesions will be treated with image-guided stereotactic ablative radiotherapy (SABR). Patients will be followed to evaluate progression-free survival, local control of treated lesions, and treatment-related adverse events (planned enrollment: \~70).

Начало: 01.11.2025 Край: 31.12.2030 Възраст: от 18 г.

China Peking University First Hospital NCT07540260

1 … 56 57 58 59 60 … 240